The MHRA has taken a different approach this year in the publication of the GMP deficiencies for drug product issued during inspections in 2018 and published in October 2019. In 2015 and 2016, MHRA provided approximately 100 slide decks with tables, figures, and text from deficiencies against the requirements in the Chapters and Annexes. No data were published for 2017. The MHRA published a 6,200-plus line excel spreadsheet of their 2018 GMP inspection data so that individuals can parse and present the data according to their needs.

This article is data-dense and includes many figures in three sections, published here in a three-part series.

  • Section I begins with a high-level overview of the 2018 data including additional trends from the two most recent MHRA reports, 2015 and 2016.
  • In Section II we identify and evaluate the critical and major deficiencies from 2018. This section identifies the Chapters and Annexes associated with critical and major deficiencies. For critical deficiencies citing Chapter 1 and Annex 1, we identify the specific paragraphs and requirements with which they are associated. 
  • In Section III we present the ten most frequently cited paragraphs for the ten Chapters and Annexes with the most frequently cited deficiencies identified in Section I, Figure 5
  • Section IV provides conclusions.

In Part 1 of this series, we cover Sections I and II. Parts 2 and 3 will cover Sections III and IV.

[NOTE: You don’t have to wait for Parts 2 and 3—download the full, 16-page report for yourself now!]

MHRA GMP Inspection Deficiencies for 2018

Background

I found the “Notes and Guidance” segment of the MHRA spreadsheet a bit confusing. In light of this, here’s how I’ve parsed the data. Each row in the spreadsheet is treated as a unique deficiency, regardless of whether it is a “deficiency” or a “sub-point” as identified in the “Notes and Guidance” section of the MHRA publication. I cannot discern which is which in the spreadsheet, so I treat them all equally.

The summary data from 2015 and 2016 are taken directly from the MHRA 2016 report. Data were not posted for 2017. Any mistakes in this analysis and reporting of the 2018 data are mine, not the MHRAs.

I. Overall Data

The MHRA conducted 285 GMP inspections, both domestic and outside of the UK, in 2018. Inspections outside the UK were conducted in Bangladesh, China, India, Japan, Singapore, South Korea, and the United States. Country specific data, other than that provided for the UK and “overseas,” was not provided in the 2015 and 2016 MHRA reports. The 285 inspections from 2018 reflect a decrease from the number of inspections conducted in both 2015 and 2016.

Figure 1 identifies the number of drug product inspections, by country, performed by the MHRA in 2018. As in past years, almost all MHRA inspections were conducted in the UK. The percentage of inspections conducted in the UK in 2018 increased slightly from 2015 and 2016 and the percentage of overseas inspection decreased slightly in 2018 to 20 percent of the total.  

In 2018, the largest number of inspections conducted outside the UK were performed in India with a total of 43. The remaining 14 inspections outside the UK were conducted in six countries with China and the US each having been the subject of five inspections, and the other countries had one each.

Figure 2 shows the trends including all classification of deficiencies from 2015, 2016, and 2018 identified in the top ten Chapters and Annexes. Data from 2015 and 2016 are taken directly from the 2016 report published by the MHRA. Quality Systems leads the list in all three years. Notable changes in 2018 from the two previous years include:

  • Outsourced Activities (Chapter 7) appears within the top ten in 2018 though it did not appear in either of the two other years.
  • Personnel (Chapter 2) is no longer among the top ten in 2018.
  • Computerized Systems (Annex 11) remains within the top ten in 2018 though it has fallen from fifth place in 2015 to seventh in 2016 to tenth place in 2018.
  • Complaints and Recalls (Chapter 8) also diminishes in rank over the time period from second in 2015, to fourth in 2016 and eighth in 2018.

Figure 3 and Figure 4 present the total number of deficiencies according to the GMP Chapter or GMP Annex cited, respectively. These figures include all deficiency classifications, critical, major, and others. Annex 15, Qualification and Validation, and Annex 1, Sterility Assurance, take first and second place among the most frequently cited annexes with approximately 600 and 450 deficiencies, respectively. This is followed by Annex 11, Computerized Systems, and Annex 16, Certification by a Qualified Person and Batch Release. All other Annexes are associated with a double-digit or fewer number of deficiencies.  

Chapter 1, Quality Management, with approximately 1500 citations has more than twice the number of deficiency citations as the nearest chapter.  Chapter 4, Documentation, with almost 760 deficiencies is closely followed by Chapter 5, Production, with just over 650, and Chapter 3, Premises and Equipment, at just under 570 citations. Chapters 2, 6, 7 and 8 each had between 200 and 400 deficiencies and the remaining two chapters had fewer than 50 and 1 citation respectively. 

Figure 3: Inspection Citations by GMP Chapter

Figure 4: Inspection Citations by GMP Annex

Figure 5 shows the top ten categories when values from Annexes and Chapters are combined, the same information provided in Figure 2 with the number of associated deficiencies. Again, this includes all categories of deficiencies. We will identify the top ten citations in each of these in Parts 2 and 3.

Figure 5: Top Ten Chapters and Annexes Cited in Deficiencies

II. Critical and Major Deficiencies

Figure 6 provides a tabulation of all 2018 deficiencies by their classification. Critical deficiencies clearly constitute the smallest category and we will provide additional detail on them later. Major deficiencies constitute almost 40 percent of the total and other deficiencies constitute the majority of the deficiencies at almost 60 percent of the total.

Figure 6:  Number of Deficiencies by Classification in 2018

The majority of critical and major deficiencies among the 6,200-plus deficiencies cluster in a few Chapters and Annexes. Figure 7 shows the number of critical deficiencies and the Chapters or Annexes which are referenced. Among the critical deficiencies, 37 percent are associated with Chapter 1, Quality Systems, and 22 percent are associated with Annex 1, Sterility Assurance. Annexes 1 and 11 are the only other Annexes that include citations for critical deficiencies, the remainder cites GMP Chapters.

Figure 7:  Critical Deficiencies

Figures 8 and 9 provide the specifics on the citations for Chapter 1 and Annex 1 respectively. The table includes the identifying paragraph, the number of times the deficiency was cited, and a short version of the text in the GMP guide.  

Figure 10 shows twelve Annexes and Chapters associated with major deficiencies and the number of times they were cited. In addition to these twelve Chapters and Annexes, major deficiencies were identified in Chapter 9 (11), Annex 2 (4), Annex 8 (8), Annex 3 (3), Annex 13 (3), and one each in Annex 6 and Annex 19. More GMP Chapters and Annexes were cited in major deficiencies than were cited in critical deficiencies. Among the major deficiencies, 33 percent are associated with Chapter 1, 11 percent are associated with Annex 15, 11 percent are associated with Annex 1, and 10 percent are associated with Chapter 5. Shortcomings in Quality Systems clearly leads the list of both critical and major deficiencies demonstrating the agencies’ focus on the importance of a sound Quality System to GMP compliance.  

Figure 10:  Major Deficiencies

In Part 2, we will continue with a granular look at the individual Chapters and Annexes identified here and how the deficiencies are divided among the various paragraphs.

[NOTE: You don’t have to wait for Parts 2 and 3—download the full, 16-page report for yourself now!]

MHRA GMP Inspection Deficiencies for 2018

Download the Special Report

Quality Week report sidebar

What You Will Learn from This Report:

How a major pharmaceutical company designed a program to train future leaders in quality

An industry-led initiative to advance the state of quality in the pharma industry

A pharma GMP leader’s tips for supporting quality culture within an organization

An update on FDA’s Quality Maturity Model

Redica Systems Enforcement Analytics

Compare two companies of your choice.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Evaluate Your CDMOs

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Compare the inspection history of your CDMO sites.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Compare the enforcement history of your CDMOs.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Monitor compliance at your Clinical Investigator sites.

Enter your email address and someone will contact you shortly to get you started.

Redica Systems Enforcement Analytics

Prepare for inspections of Clinical Investigator sites.

Enter your email address and someone will contact you shortly to provide more Clinical Investigator data about your sites.

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore enforcement trends. 

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore observations and trends. 

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to run your custom report.

Redica Systems Enforcement Analytics

Get help choosing the right CRO.

Enter your email address and someone will contact you shortly to customize your insights.

Download the Special Report

Download your copy of THE FDA INSPECTION LANDSCAPE IN MID-2020 AND A LOOK AT VIRTUAL INSPECTION

In this summary we identify:

  • Trend analysis of FDA inspections through mid-2020
  • Strategies for preparing and hosting virtual inspections
  • New technologies to support remote inspections
Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need to prepare for your next inspection.

Download the Special Report

CDMO Comparison opt-in

In this summary we identify:

FY2018-FY2020 GMP data for Lonza & Catalent

Top GMP primary citations

Top FDA 483 observations

Panel Discussion – Remote Audits

Panel Discussion opt in image

Featuring Panelists:
—Barbara W. Unger, Unger Consulting, Inc.
—Jerry Chapman, Redica Systems
—Stephanie Gaulding, Pharmatech Associates

Who Will Benefit?
This session will be valuable to GMP quality, regulatory, compliance, and management personnel in FDA-regulated industries who want to have a conversation on remote audits and get to know what is going on in the industry.

Turning Failure into Success

Presented on Tuesday, April 27, 2021 by Steve Greer, Executive Coach, Genesis Assist, and former Quality Leader, Procter and Gamble

What you will learn:

  • How to use the Leadership SOS Model to transform quality culture
  • How to strengthen quality systems to eliminate human error
  • How to generate ideas on how to set your organization up for success for shareholders, FDA, and staff
Redica Systems Enforcement Analytics

Get Full Access to Redica Enforcement Analytics

Enter your email address and someone will contact you shortly to answer all of your questions and get you started.

Quality Management Systems for Small Pharma and Biotech Firms

Webinar: QMS for Small Pharma and Biotech Firms

Presented by Fenton Fong, Founder, Managing Director, & Principal at xCellarate

Get instant access to the webinar video and slides.

What you will learn:

  • Common challenges small pharma firms face when developing a QMS
    Recent enforcement trends involving the Quality Unit
    Impact of the COVID-19 pandemic

Download the Special Report

APAC ad

In this summary we identify:

GMP data from FY2017 to FY2020 for the Asia-Pacific region

Top 3 GMP primary and secondary citations

Top 3 483 observations

Download the Special Report

An Analysis Of MHRA’s Latest Annual GMP Inspection Deficiencies Report

In this summary we identify:

  • Data from 2019 UK MHRA Inspections
  • Trends from 2015, 2016, 2018, and 2019 inspections
  • Conclusions drawn from an analysis of drug inspection data

Experience the Power of Redica Systems

Redica_Vert_Periwinkle_RGB_Large

SEARCH Find the inspection records you want by inspector’s name, company name, site, city, country, etc.

WARNING LETTERS Easily search the largest database of FDA Warning Letters by date, company, FDA office, or subject

SITES Quickly assess inspection records including dates and inspectors across all of your sites

INSPECTIONS Complete list of FDA inspections by date, company, category, and country

Get Complete Access to the Redica Systems Platform

Please submit your email address and one of our team members will contact you shortly to answer all of your questions and get you started with the new Enforcement Analytics platform.

Experience the Power of Redica Systems

Complete the form and one of our experts will reach out to you to schedule a demo and answer questions about our subscription options.

INDEX INFORMATION  Redica consolidates regulatory data in real-time on the single largest database for quality, safety, and compliance intelligence.

STRENGTHEN DATASETS Redica machine intelligence algorithms identify and triage risk signals to derive meaning from vast amounts of private and public data.

ANALYZE & INTERPRET PATTERNS Redica instantly models the customer-specific regulatory risks, trends, and opportunities that stand to fundamentally change compliance operations.

Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Impact of the Global Pandemic on Recent Data Integrity and Regulatory Non-compliance Trends

Webinar: Impact of the Global Pandemic on Recent Data Integrity and Regulatory Non-compliance Trends

Presented by Paul Smith, Agilent Technologies on Aug. 26, 2020

What you will learn:

  • Examples of essential laboratory actions to remain compliant during the pandemic
  • Recent data integrity non-compliance findings and trends
  • Essential strategies to find, understand, and leverage regulatory non-compliance data

Get the scoop on recent data integrity 483 observations!

  • FY 2020 Data Integrity 483 Observations
  • Data Integrity Observations for Human Drugs
  • Observations Falling Under GMP
  •  

Past, Present, and Future of Quality Culture

Presented by Regulatory Compliance Associates Distinguished Fellow Susan Schniepp

What you will learn:

  • How the 2014 FDA quality metrics initiative led to greater focus on quality culture
  • New quality culture tools and standards under development by PDA and other organizations
  • Best practices for quality culture, including case studies with lessons learned

Changing Medical Device Regulations

Presented by Redica Systems 

What you will learn:

  • The latest developments regarding the EU MDR
  • Quality Systems requirements for medical devices
  • Regulatory updates affecting medical devices

Download the Special Report

Combination Product Report

What You Will Learn from This Report:

The latest U.S. and European regulatory developments

The impact of smart combination products

How the EU MDR impacts drug-device combination products

Download the Special Report

5 GMP Case Studies Report

What You Will Learn from This Report:

In-depth analysis of the findings

Lessons learned

How companies can avoid similar shortcomings.

Experience the Power of Redica Systems

Redica Systems Expert Jerry Chapman to Present at SQA Annual Meeting

Index Information Redica consolidates regulatory data in real-time on the single largest database for quality, safety, and compliance intelligence.

Strengthen Datasets Redica machine intelligence algorithms identify and triage risk signals to derive meaning from vast amounts of private and public data.

Analyze & Interpret Patterns Redica instantly models the customer-specific regulatory risks, trends, and opportunities that stand to fundamentally change compliance operations.

Download the 510(k) Sample

What You Will Learn from This Sample:

See how a 510(k) submission is structured

Find out what information to include

Review correspondence between sponsor and FDA

Redica Systems Enforcement Analytics

Unlimited Access to Reports and Data

Enter your email address and someone will contact you shortly.

Download the Special Report

5 GMP Case Studies Report

What You Will Learn from This Report:

The first countrywide import alert issued by FDA

An inadequate deviation investigation

An inadequate product specifications and a product recall

Process validation issues at a CMO

A different perspective on process validation and the culpability of the quality unit

 

A.I. for Quality and Compliance Teams

August 3 webinar

Presented by Redica Systems Senior GMP Quality Expert Jerry Chapman

What you will learn:

  • A basic understanding of data sources, machine learning, NLP, and A.I. tools
  • Building and applying Expert Models
  • Two case studies, one on sterile manufacturing/503B and one on data integrity

Human Factors – Compliance and Applications

June webinar

Presented by Alison Sathe, Founder, Regulatory Mark & Valerie Fenster, Director of Insights and  Human Factors, Kaleidoscope Innovation 

What you will learn:

  • Human factors strategies from simple drug products to complex surgical devices
  • Primary and secondary labeling development and evaluation for usability
  • Human factors activities from product development to post-market
  • International strategies: expectations for human factors in regulatory submissions in international markets

Experience the Power of Redica Systems

Redica Systems Enforcement Analytics

Sign up for your FREE account today and get instant access to Enforcement Analytics.

Experience the Power of Redica Systems

Redica Systems Enforcement Analytics

Let us know who you are and we’ll be in touch to answer all of your questions and get you started.

Redica Systems Enforcement Analytics

Keep up with the latest Regulatory Developments on Clinical Trials

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Save your team valuable time when using External Monitoring.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Save time and Resources when using External Monitoring.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Get immediate access to the news that matters to your sites.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

See how we can help you eliminate yet another spreadsheet.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Stay ahead of changing regulations.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Redica Systems Enforcement Analytics

Upgrade your CDMO monitoring strategy.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Redica Systems Enforcement Analytics

Upgrade your CDMO management strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Discover the power of the most comprehensive database of 483s in existence.

Our database of over 20,000 483s is retyped and tagged, making it easy to create an Observation Report in seconds.

Eliminate days of work and get your FREE personalized 483 Observation Report.